Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-02
1999-11-30
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514522, A61K 3144, A61K 31275
Patent
active
059943629
ABSTRACT:
Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5.alpha.-reductase inhibitor, i.e., a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.
REFERENCES:
patent: 4039669 (1977-08-01), Beyler et al.
patent: 5175155 (1992-12-01), Juniewicz et al.
patent: 5300294 (1994-04-01), Johnson
patent: 5593981 (1997-01-01), Labrie
patent: 5595985 (1997-01-01), Labrie
patent: 5610150 (1997-03-01), Labrie et al.
Labrie et al., Endocrinology 128(3) 1991, pp. 1673-1675, "Combination of an antiandrogen and a 5alpha-reductase inhibitor" .
Andriole et al., The Prostate 10 (1987), pp. 189-197, "The effect of 4MA, a potent inhibitor of 5alpha-reductase, on the growth of androgen-responsive human genitourinary tumors . . . ".
Liang et al., J. of Biol. Chem., 256(15), 1981, pp. 7998-8005, "Inhibition of 5alpha-reductase, receptor binding, and nuclear uptake of androgens in the prostate . . . ".
Petrow et al, Steroids 38(2), 1981, pp. 121-140, "Prostatic cancer. I. 6-methylene-4-pregnen-3-ones as irreversible inhibitors of rat prostatic . . . ".
Ito et al, J. Pharm. Pharmacol. 41 (1989), pp. 488-489, "A new approach to prostate cancer".
Kadohama et al., JNCL, vol. 74(2), 1984, pp. 475-486, "Retardation of prostate tumor progression in the noble rat by 4-methyl-4-aza-steroidal inhibitors of 5alpha-reductase".
Raynaud et al., Bull. Cancer (Paris), vol. 73(1), 1986, pp. 36-46, "Cancer de la prostate" Bases biologiques pour l'emploi d'un antiandrogene dans le traitement.
Petrow et al., The Prostate, vol. 9, 1986, pp. 343-361, "The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications".
Petrow et al., The Prostatic Cell: Structure and Function, Part B, (1981), pp. 283-296, "Studies on a 5alpha-reductase inhibitor and their therapeutic implications".
Sandberg et al., Progress in Cancer Research and Therapy, vol. 31 (1984), pp. 477-489, "Enzymatic and receptor systems as targets for therapy of prostatic cancer".
Isaacs et al., The Prostate, 1989, pp. 33-40, "Experimental studies on optimal therapy for prostatic cancer".
Stone et al., The Prostate, 1986, pp. 311-318, "Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia".
Olea et al., Endocrinology 126(3), 1990, pp. 1457-1463, "The proliferative effect of 'anti-androgens' on the androgen-sensitive human prostate cell line LNCaP".
Furr et al., UK. European Urology (1990) 18 Suppl., 3, pp. 2-9.
Pode et al., European Urology (1990) 18 Suppl 1, p. 177.
Gormley Glenn J.
Stoner Elizabeth
Fitch Catherine D.
Goldberg Jerome D.
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Method of treatment for prostatic cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for prostatic cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for prostatic cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1672972